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ABSTRACT 36 
Numerous links exist between co-transcriptional RNA processing and the transcribing 37 
RNAPII. In particular, pre-mRNA splicing was reported to be associated with slowed RNAPII 38 
elongation. Here we identify a site of ubiquitination (K1246) in the catalytic subunit of RNAPII 39 
close to the DNA entry path. Ubiquitination was increased in the absence of the Bre5-Ubp3 40 
ubiquitin protease complex. Bre5 binds RNA in vivo, with a preference for exon 2 regions of 41 
intron-containing pre-mRNAs and poly(A) proximal sites. Ubiquitinated RNAPII showed 42 
similar enrichment. The absence of Bre5 led to impaired splicing and defects in RNAPII 43 
elongation in vivo on a splicing reporter construct. Strains expressing RNAPII with a K1246R 44 
mutation showed reduced cotranscriptional splicing. We propose that ubiquinitation of 45 
RNAPII is induced by RNA processing events and linked to transcriptional pausing, which is 46 
released by Bre5-Ubp3 associated with the nascent transcript.  47 
 48 
 49 
INTRODUCTION 50 
Over recent years it has become increasingly clear that there are numerous, functionally 51 
important links between co-transcriptional RNA processing and the changes occurring on 52 
the transcribing RNA polymerase II (RNAPII). Most attention has focused on modifications of 53 
the regulatory C-terminal domain (CTD) of the large, catalytic subunit of RNAPII, which 54 
promote the ordered recruitment of numerous RNA packaging and processing factors to the 55 
nascent pre-mRNAs. However, there is also evidence that RNA processing events can 56 
affect the transcription machinery. In particular, it has been proposed that pre-mRNA splicing 57 
is associated with slowed RNAPII elongation in yeast (Alexander et al., 2010b; Carrillo 58 
Oesterreich et al., 2010), which presumably favors cotranscriptional splicing. In addition, an 59 
elongation “checkpoint” exists upstream of the 3’ cleavage and polyadenylation site in 60 
human cells (Laitem et al., 2015). These presumably reflect changes in the transcription 61 
machinery that are distinct from phosphorylation of the RNAPII CTD. 62 
 63 
Analyses of the effects of UV-induced DNA damage revealed that RNAPII stalled at sites of 64 
DNA lesions undergo ubiquitination of the large polymerase subunit (termed Rpo21 or Rpb1 65 
in yeast) (Kvint et al., 2008). RNAPII ubiquitination following DNA damage was reported to 66 
be a multi-step process, with initial mono-ubiquitination by Rsp5, followed by 67 
polyubiquitination by an Ecl1-Cul3 complex (Harreman et al., 2009). The stalled polymerase 68 
can be deubiquitylated by the ubiquitin protease Ubp3, and failure of this activity leads to 69 
increased degradation of the polymerase by the proteasome. During the DNA damage 70 
response Ubp3 functions together with a cofactor Bre5 (Bilsland et al., 2007), with which it 71 
stably associates (Li et al., 2005). In addition, Ubp3 was identified as a factor physically 72 
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associated with the transcription silencing factor Sir4 and loss of Ubp3 was reported to 73 
increase the efficiency of gene silencing near telomeres and at the inactive HML mating type 74 
locus (Moazed and Johnson, 1996). The Bre5-Ubp3 heterodimer also protects the TATA-75 
binding protein Tbp1 against degradation (Chew et al., 2010), as well as functioning in a 76 
number of other, apparently unrelated pathways, including vesicle trafficking (Baxter et al., 77 
2005; Cohen et al., 2003; Ossareh-Nazari et al., 2010) and starvation induced autophagy of 78 
mature, cytoplasmic ribosomes (ribophagy) (Kraft et al., 2008). Possibly related to this, Bre5-79 
Ubp3 also interacted genetically with the ribosome synthesis factor Nep1 (Schilling et al., 80 
2012). Moreover, Bre5 was identified in a proteomic screen for proteins associated with 81 
poly(A)+ RNA (Mitchell et al., 2013). 82 
 83 
In order to identify new factors involved in RNA surveillance in yeast, genetic screens were 84 
performed, in which collections of strains individually deleted for each of the ~5,000 non-85 
essential genes were crossed en masse to strains lacking a single test gene (Decourty et al., 86 
2008; Milligan et al., 2008). Following sporulation of the diploids generated, double mutant 87 
haploids were selected and allowed to grow for several generations. The mixed culture was 88 
then harvested, and the representation of each gene in the collection determined by 89 
microarray analysis. Unexpectedly, these competitive growth tests identified Bre5 and Ubp3 90 
as showing the strongest, synergistic, negative growth defects with the non-essential, 91 
nuclear RNA surveillance factors Rrp47, which binds and activates the nuclease Rrp6, and 92 
the Air1 and Trf5 components of the TRAMP5 nuclear polyadenylation complex, which 93 
functions together with the exosome (Decourty et al., 2008; Houseley and Tollervey, 2006; 94 
Losh et al., 2015; Milligan et al., 2008; Schuch et al., 2014; Stuparevic et al., 2013). 95 
 96 
The initial aim of this work was therefore to determine whether and how Bre5 and Ubp3 are 97 
linked to nuclear RNA metabolism.  98 
 99 
 100 
101 
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RESULTS 102 
Bre5 is an RNA binding protein that shows preferential association with exon 2 of 103 
spliced pre-mRNAs 104 
In genome-wide synthetic lethal screens bre5∆ and ubp3∆ were each identified as showing 105 
strong synergistic negative growth with the exosome cofactors rrp47∆, air1∆ and trf5 106 
(Decourty et al., 2008; Milligan et al., 2008).  107 
 108 
The crystal structure of Bre5 (Li et al., 2005) suggested the presence of a C-terminal RNA-109 
recognition motif. The ability of Bre5, Ubp3 and the Bre5-Ubp3 dimer to bind RNA and single 110 
stranded DNA was therefore tested in vitro (Fig. 1A). Recombinant Bre5 and Ubp3 were 111 
expressed by in vitro translation singly or in combination using a TNT kit (Promega) and 112 
tested for binding to biotinylated oligos (A, A/U and dT) as previously described (Milligan et 113 
al., 2008). This showed that Bre5 bound to weakly to oligo(A), more strongly to oligo(U/A), 114 
and best to oligo(dT). Ubp3 alone showed little binding activity, but was recovered in the 115 
bound fraction when expressed together with Bre5. We concluded that Bre5 and the Bre5-116 
Ubp3 complex can bind RNA and single stranded DNA in vitro. 117 
 118 
To confirm this, the ability of Bre5-Ubp3 purified from yeast to bind RNA was also tested. For 119 
this, Bre5 was expressed as fusion with a C-terminal, tripartite HTP tag (His6-TEV cleavage 120 
site-2x Protein A) under the control of the endogenous BRE5 promoter. Bre5-HTP was 121 
purified by binding to an IgG column under native conditions (Figure 1 Supplement 1C). As 122 
negative control a lysate from the wild type strain (BY4741) lacking the tagged form of Bre5 123 
was also mock purified on IgG. As positive control the RNA binding protein Nab3-HTP 124 
(Holmes et al., 2015) was also purified and assessed for binding. Radiolabeled RNA 125 
oligonuclotides (oligos) were incubated with the IgG column and then washed extensively. 126 
Bound oligos were eluted, gel purified and quantified using a phosphor screen and Fuji 127 
scanner. The oligos used included the homopolymers, A20, U20, G20 and C20 (Fig.1B and 128 
Fig.1 Supplement 1A). In addition, in vivo Bre5 binding sites identified by CRAC were 129 
analyzed to identify enriched motifs (see below). This identified the motif UUUG (Fig. 1 130 
Supplement 1B) as the preferred in vivo target for Bre5. Oligos were generated with three 131 
copies of UUUG, interspersed and flanked with either A residues (oligo Bre5-A) or U (oligo 132 
Bre5-U) (see legends to Fig. 1 and Fig. 1 Supplement 1). The consensus Nab3 binding site 133 
(UUCU) was used to generate similar oligos (Nab3-A and Nab3-U). 134 
 135 
Relative to the column loaded with lysate from the untagged strain, the column loaded with 136 
Bre5-HTP recovered ~1.5 fold more oligo(A), 2 fold more oligo(U), but similar levels of 137 
oligo(G) and oligo(C) (Fig. 1B and Fig. 1 Supplement 1). Strikingly the strongest binding was 138 
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observed for the Bre5-U oligo on the Bre5 column; 6 fold greater than the BY control. 139 
Substantial binding was also seen for the Nab3-U oligo, which differs in only three positions 140 
from Bre5-U (Fig. 1B). Binding to the Nab3 column was significantly different from Bre5, with 141 
strong association of the Nab3-A and Nab3-U oligo, but low association with the Bre5 target 142 
oligos (Fig. 1B and Supplementary File 1, Table S2). We conclude that Bre5 can bind RNA 143 
in vitro, with some sequence specificity.  144 
 145 
To determine whether Bre5 also directly binds RNA in vivo, we used the approach of UV 146 
crosslinking and analysis of cDNA (CRAC) (Granneman et al., 2009). Actively growing 147 
cultures expressing Bre5-HTP were briefly UV-irradiated (100 sec) and Bre5-HTP was 148 
recovered under stringent, denaturing conditions. Bound RNA was partially degraded, 149 
amplified by RT-PCR and identified by Illumina sequencing. Mapping the reads to the yeast 150 
genome (Fig. 1C) showed a predominance of RNAPII targets, particularly protein coding 151 
genes, although hits in rRNA and tRNAs were also recovered at lower frequency. Compared 152 
to Bre5, the untagged control recovered an average of ~15 fold fewer total reads following 153 
PCR amplification. Numbers of mapped reads are indicated below the bar graphs in Figure 154 
1C. 155 
 156 
A metagene analysis of the distribution of Bre5 binding across all protein-coding genes was 157 
performed (Figs. 1D-1G). Alignment by the transcription start site (TSS) revealed marked 158 
depletion of Bre5 over the promoter proximal region of ~150 nt relative to sites further 3’ 159 
(Fig. 1D). In contrast, strong enrichment was seen for Bre5 binding ~200 nt upstream from 160 
the mRNA 3’ cleavage and polyadenylation sites, followed by a sharp decrease (Fig. 1E). 161 
Comparison of Bre5 binding on intron-containing, protein coding genes aligned by the 3’ 162 
splice site showed enrichment on the exon 2 regions relative to exon 1 or introns (Fig. 1F). 163 
Since Bre5 binding is elevated close to the poly(A) site, it seemed possible that this was 164 
responsible for the apparent exon 2 signal. However, stratifying the data by exon 2 length 165 
revealed that the high signal at the 5’ end of exon 2 persisted even on genes with exon 2 166 
longer than 600nt (Fig. 1G). Bre5 binding was most marked on genes with relatively short 167 
exon 2 sequences (Fig. 1H), on which transcription pausing is reported to be stronger 168 
(Carrillo Oesterreich et al., 2010). We also examined the distribution on Bre5 on individual 169 
genes (Fig. 1 Supplement 2). This showed the same trends as the metagene analysis. 170 
 171 
To identify potential preferred targets for Bre5 binding in vivo, sequences generated by 172 
CRAC were analyzed to identify potential recognition motifs using MEME (see Experimental 173 
Procedures). Analyses of two independent, replica data sets each identified the motif UUUG 174 
as the strongest interaction target, present in 70% of target sequences analyzed (e >10-120). 175 
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As a positive control, CRAC data for the RNA binding protein Nab3 (Bresson et al., 2017) 176 
were similarly analyzed and identified the previously reported UUCU binding site. Analysis of 177 
negative control data from the BY control strain, Rpo21 (the large subunit of RNAPII) or the 178 
histone methyl-transferases Set1 and Set2 (Sayou et al., 2017), identified no clearly 179 
enriched motifs. 180 
 181 
Bre5 forms a stable dimer with the ubiquitin protease Ubp3 (Li et al., 2005), suggesting that 182 
Bre5 might be recruited to nascent transcripts through binding of Ubp3 to ubiquitinated forms 183 
of RNAPII or other transcription factors. To assess this, crosslinking of Bre5-HTP was 184 
performed in a ubp3∆ strain. In the absence of Ubp3 we saw increased relative Bre5 binding 185 
close to the TSS, whereas binding in exon 2 and close to the poly(A) site was not clearly 186 
altered (Fig. 1 Supplement 1 D, 1E, 1F). This observation indicates that the major pathway 187 
for Bre5 recruitment does not involve Ubp3 binding to ubiquitinated substrates. Rsp5 was 188 
previously reported to ubiquitinate Rpo21 (Harreman et al., 2009), so Bre5-HTP crosslinking 189 
was also tested in an rsp5-3 temperature sensitive (ts) strain (Neumann et al., 2003) 190 
following transfer to non-permissive temperature (37°C). No clear differences were observed 191 
close to the TSS or poly(A) sites. A modest reduction was observed in Bre5 binding to 192 
RNAPII transcripts at the 5’ ends of exon 2 regions (Fig. 1 Supplement 1G, 1H, 1I). It is 193 
unclear whether this is a direct consequence of reduced activity of Rsp5, which is highly 194 
pleiotropic.  We conclude that Bre5 can bind RNAPII transcripts independently of Ubp3, with 195 
elevated binding in exon 2 regions of spliced pre-mRNA and upstream of the 3’ cleavage 196 
and polyadenylation sites.  197 
 198 
To assess binding of Bre5 to unspliced pre-mRNAs relative to splicing products, the number 199 
of reads spanning the spliced (exon-exon, EE) to unspliced junctions (exon-intron, EI and 200 
intron-exon, IE) was calculated as 2EE/(EI+IE) for each transcript and averaged between 201 
replicates (Milligan 2016; Tuck and Tollervey 2013). An 2EE/(EI+IE) ratio >1 indicates 202 
preferential binding after pre-mRNA splicing. For the large subunit of RNAPII, Rpo21, the 203 
2EE/(EI+IE) ratio was 0.2, showing the expected association with unspliced nascent 204 
transcripts. For Bre5, the ratio was 30, indicating preferential binding to the spliced products 205 
(Supplementary File 1, Table S2). Notably, the 2EE/(EI+IE) ratio was further increased for 206 
Bre5 in the ubp3∆ strain, largely due to reduced intron binding, indicating that Upb3 does 207 
contribute to early pre-mRNA recruitment of Bre5. In contrast, no clear differences were 208 
seen in the Bre5 strain also carrying the ts-lethal rsp5-3 mutation at either 23°C or 37°C.  209 
 210 
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We interpret the results in Fig. 1 and Fig. 1 Supplement 2 and Supplementary File 1, Table 211 
S2, as indicating that Bre5-Ubp3 associates with the transcript following the successful 212 
completion of splicing. 213 
 214 
Loss of Bre5 results in RNAPII stalling and decreased mRNA on an inducible reporter  215 
Inspection of the distribution of Bre5 hits over exon 2 of pre-mRNAs, showed that binding 216 
was highest on genes with short exon 2 regions (Figs. 1F, G and H). Previous analyses 217 
have reported that pre-mRNA splicing is associated with transcription pausing on exon 2, 218 
which is more frequent on genes with short exon 2 regions, perhaps to allow time for 219 
cotranscriptional splicing (Alexander et al., 2010b; Carrillo Oesterreich et al., 2010). 220 
 221 
To test for effects of Bre5 on transcription pausing by RNAPII we made use of “RiboSys” 222 
reporters, which were developed to generate kinetic data for pre-mRNA transcription and 223 
splicing (Alexander et al., 2010a). The RIBO1 reporter (Fig. 2A) contains part of the PGK1 224 
open reading frame with the insertion of the ACT1 pre-mRNA intron, integrated into the 225 
chromosomal HIS3 locus under the control of an inducible tetO7 promoter. Following 226 
induction by addition of doxycycline, samples were analyzed for pre-mRNA and mRNA 227 
levels by RT-PCR, and RNAPII occupancy by chromatin immunoprecipitation (ChIP) at five 228 
locations along the reporter (probes 1-5 in Fig. 2A).  229 
 230 
Notably, these analyses reveal the initial time course of induction of an intron-containing 231 
transcript expressed from “naïve” chromatin. In the wild-type strain, pre-mRNA was detected 232 
after 5 min, followed by the appearance of spliced mRNA at 6 min (Fig. 2B). The mRNA 233 
levels then climbed progressively while pre-mRNA levels remained relatively constant. In the 234 
bre5∆ strain, pre-mRNA and mRNA were also detected after 5 min and 6 min, respectively. 235 
However, subsequent pre-mRNA levels were higher than in the wild-type, and mRNA failed 236 
to strongly accumulate. We conclude that splicing of the pre-mRNA reporter is strongly 237 
inhibited in the absence of Bre5. 238 
 239 
In the wild-type, RNAPII levels show a striking periodicity following induction of the reporter 240 
(Fig. 2C-G), as previously reported (Alexander et al., 2010b). In the bre5∆ strain, this 241 
periodicity was disrupted, with longer apparent pause durations. Notably, at the 5’ splice site 242 
there is little clear pausing in the wild-type but much stronger signals in bre5∆ strains (Probe 243 
2). In contrast, the wild-type RNAPII signals are high in the 3’ region of exon2 (Probe 5), but 244 
much lower in bre5∆, suggesting that RNAPII is delayed or lost prior to this region in the 245 
mutant. The accumulation of RNAPII in the vicinity of the 5’ splice site (probe 2) was initially 246 
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surprising, but there is a clear precedent in a previous report (Chathoth et al., 2014) that 247 
defects in pre-mRNA splicing lead to the accumulation of RNAPII at the 5’ SS. 248 
 249 
We interpret the data as showing that the oscillation in RNAPII association with the splicing 250 
reporter seen following initial induction is slower in the bre5∆ strain. Polymerase density in 251 
increased in the 5’ region of the transcription unit and decreased towards the 3’ end. These 252 
findings would be consistent with a delay in the release of paused or slowed polymerases. 253 
 254 
Notably, a reporter with a single nucleotide mutation at the 5’ splice site that blocks splicing 255 
showed similar pre-mRNA, mRNA and RNAPII ChIP signals in wild-type and bre5∆ strains 256 
(Fig. 2 Supplement 1). This shows that the effects of Bre5 are specifically linked to pre-257 
mRNA splicing. The putative ubiquitin ligase involved in the Bre5-dependent changes has 258 
not yet been identified. Ubr2 shows genetic and physical interactions with Bre5 and splicing 259 
factors (Albers et al., 2003; Collins et al., 2007; Costanzo et al., 2010). However, its absence 260 
did not clearly alter mRNA production or RNAPII elongation in the reporter construct (Fig. 2).  261 
 262 
Loss of Bre5 affects splicing on endogenous genes  263 
To test the relative effects of Bre5 on cotranscriptional versus post-transcriptional splicing of 264 
endogenous genes, we assessed the timing of splicing relative to pre-mRNA cleavage and 265 
polyadenylation (Fig. 3). Unspliced but polyadenylated RNAs have failed to undergo 266 
cotranscriptional splicing and can be identified by RT-PCR. In strains lacking Bre5, the 267 
abundance of unspliced, poly(A)+ RNA was decreased relative to spliced, poly(A)+ RNA for 268 
two spliced transcripts tested (RPL19B and RPL25) (Fig. 3A).  269 
 270 
To determine whether the apparent effect of Bre5 loss on pre-mRNA splicing requires RNA 271 
binding, point mutations were generated in the RNA recognition motif that are predicted to 272 
impair binding activity without disrupting the structure of the protein (K455E; F435A; 273 
Y421A/F453A; Y421A/R423E/F453A). The wild-type and mutant Bre5 constructs were expressed 274 
from the endogenous locus as C-terminal HTP fusions under the control of the BRE5 275 
promoter. To confirm that the point mutations impair functional RNA-binding, the wild-type 276 
and mutant forms of Bre5-HTP were compared by UV crosslinking in vivo. This was followed 277 
by purification on IgG, TEV elution, partial RNase digestion and nickel purification. 278 
Crosslinked RNAs were 5’ labeled, and RNA-protein complexes were eluted and separated 279 
on an SDS gel. The recovery of Bre5 associated RNA was determined by autoradiography 280 
(Fig. 3B, upper), while protein recovery was assessed by western blotting of the same gel 281 
(Fig. 3B, lower). This showed that recovery of the mutant proteins was similar to wild-type 282 
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Bre5, whereas each of the RRM mutations strongly reduced RNA association, with lowest 283 
binding for the Y421A/R423E/F453A triple mutant. 284 
 285 
Relative to the strain expressing wild-type Bre5, the mutant strains showed reduced levels of 286 
unspliced, poly(A)+ RNA for each of the transcripts tested (RPL19B, ACT1 and RPL25), with 287 
the strongest effect in the Y421A/R423E/F453A triple mutant (Fig. 3C). 288 
 289 
We conclude that the loss of either Bre5 or its RNA-binding function, leads to a decrease in 290 
unspliced, polyadenylated RNA, indicating increased cotranscriptional splicing. Note that this 291 
assay shows steady state levels, and includes only transcripts on which RNAPII has 292 
reached the 3’ end of the gene, whereas the RIBO1 reporter shows the effects on the 293 
kinetics of processing of nascent transcripts during initial induction. 294 
 295 
The catalytic subunit of RNAPII is ubiquitinated in the absence Bre5 or Ubp3  296 
The association of Bre5 with RNAPII transcripts in the absence of DNA damage suggested 297 
that ubiquination of RNAPII subunits and deubiquitination by Bre5-Ubp3 occurs during 298 
normal growth. To assess this all ubiquitinated proteins were purified using anti-ubiquitin 299 
antibodies, followed by western blotting for Rpo21 (Fig. 4A). In an alternative approach, 300 
RNAPII was purified using antibodies against the Rpb3 subunit, followed by western blotting 301 
with anti-ubiquitin antibodies (Fig. 4B). In both analyses, ubiquitinated Rpo21 was detected 302 
in the wild-type and was strongly elevated in cells lacking Ubp3, with a weaker increase in 303 
the absence of Bre5. In Figure 4B, the westerns were decorated with anti-Ub antibodies, 304 
which interact with free mono- and poly-ubiquitin and with all ubitiquitinated proteins in the 305 
input samples. Moreover, Bre5-Ubp3 have numerous targets in addition to RNAPII, many of 306 
which are increased in the mutant lysates.   307 
 308 
The site of ubiquitination that was sensitive to Bre5-Ubp3 activity was identified by protein 309 
purification and mass-spectrometry (MS). To affinity purify RNAPII, we made use a C-310 
terminal fusion between Rpb3 and a tripartite tag containing calmodulin binding peptide, a 311 
TEV-cleavage site and protein A (Rpb3-TAP). This was expressed from the chromosomal 312 
Rpb3 locus under the control of the endogenous promoter and was fully functional with 313 
growth being indistinguishable from the wild type. Ubiquitinated RNAPII subunits were 314 
affinity purified from wild-type, ubp3∆ and bre5∆ strains by a His6-Ubiquitin expressed from 315 
the PCUP1 promoter on a CEN plasmid, gel purified, subjected to in-gel trypsin digestion and 316 
analyzed by MS. This identified a number of sites that carried an additional lysine residue, 317 
derived from cleavage of attached ubiquitin molecules (Fig. 4C). Ubiquitination of Rpo21 318 
was detected at sites K452, K695 and K1246 in the wild-type strain. However, only 319 
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ubiquitination of K1246 was detected in the bre5∆ strain. In the ubp3∆ strain, ubiquitination 320 
was detected at K695, and multiple peptides were recovered for K1246. Ubiquitination at 321 
K695 was not clearly altered in the ubp3∆ strain. In the bre5∆ strain, ubiquitination was 322 
detected only at K1246.  A site of ubiquitination was also detected at Lys886 in Rbp2, the 323 
second largest RNAPII subunit, but ubiquitination at this site was not clearly altered by the 324 
absence of either Bre5 or Ubp3. Ubiquitin with both K48 and K63 linkages was identified in 325 
the wild-type and ubp3∆ samples, making it unclear what linkage is present at K1246.  326 
 327 
Multiple sites of ubiquitination were detected in RNAPII, and all should be enriched by 328 
purification. If ubiquitination is increased only at one site, this should be elevated relative to 329 
linear, unmodified peptides, which reflect the total recovery of Ub Rpo21. The intensities 330 
corresponding to modified peptides in each sample were normalized to the intensities of 331 
multiple, linear, non-modified peptides from Rpo21. Relative to total Ub Rpo21, the level of 332 
K1246 ubiquitination was estimated to be approximately 5 fold higher in ubp3∆ than the wild 333 
type, while the level of K695 was not clearly altered. This calculation is expected to under 334 
estimate the increased since the K1246 ubiquitination will contribute to total Ub Rpo21. 335 
Comparison to peptides from “background” proteins indicated that the abundance of K1246 336 
ubiquitination was approximately 10 fold elevated in the ubp3∆ strain. 337 
 338 
To generate better quantitation by MS, we applied a targeted acquisition methodology - 339 
PRM (Parallel Reaction Monitoring). PRM or SRM (Selected Reaction Monitoring) are widely 340 
adopted strategies utilized to perform sensitive and reproducible quantitation of peptides 341 
including ubiquitinated peptides (Gallien et al., 2014).  In brief, during acquisition, the mass 342 
spectrometer isolates only precursors corresponding to peptides of interest. The selected 343 
mass (precursor) is fragmented and obtained fragment ions are recorded. The intensity of 344 
selected fragment ions is then used for quantitation. For the analyses, Rpb3 was purified as 345 
described above, FASP digested and analyzed on an Orbitrap Fusion Lumos operated in 346 
PRM mode. Both modified (VVRPK*SLDAETEAEEDHMLK) and unmodified (VVRPK) 347 
peptides were readily detected in all samples containing Rpo21 co-purified with Rpb3-HTP 348 
(wild type, bre5Δ and ubp3Δ) and not in an untagged strain. Quantitation was performed on 349 
y10-y18 fragment ions by averaging intensity of the most intense ions between the replicas. 350 
These analyses indicated that levels of K1246-Ub in bre5Δ and ubp3Δ are 1.6 and 10.5 351 
times higher, respectively, than in the wild type (Fig. 4D). We conclude that loss of Bre5-352 
Upb3 specifically increases ubiquination of Rpo21 at K1246.  353 
 354 
The ubiquitination site at K1246 is located in an acid loop that is unstructured and therefore 355 
absent from published RNAPII crystal structures (Fig. 4E) (Sainsbury et al., 2013). However, 356 
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the position of the base of this loop (P1245 and E1253; residues shown as space filling in 357 
Fig. 4E) strongly indicates that the site of ubiquitination lies close to the entrance to the 358 
active site of the polymerase. Ubiquitin in this position appears likely to clash with the entry 359 
of the DNA duplex into the active site (Fig. 4F), and may also interfere with binding of 360 
transcription elongation factors, potentially explaining the basis for stalling of RNAPII by 361 
ubiquitination. 362 
 363 
Ubiquinated RNAPII is enriched over exon 2 of intron-containing genes 364 
To map the locations of RNAPII containing ubiquitinated Rpo21, we applied modification 365 
CRAC (mCRAC) (Fig. 5A) (Milligan et al., 2016). As for CRAC analyses, Rpo21-HTP was 366 
UV-crosslinked in actively growing cells and tandem affinity purified under denaturing 367 
conditions, prior to identification of associated RNAs by RT-PCR and Illumina sequencing. 368 
This allows strand-specific mapping of the locations of modified RNAPII, with nucleotide 369 
resolution. During purification, ubiquitinated proteins were specifically enriched using a 370 
MultiDsk construct, comprised of five UBA domains from the yeast ubiquitin-binding protein 371 
Dsk2 fused to GST (Wilson et al., 2012). This binds ubiquitinated proteins with high affinity 372 
and specificity (Fig. 5 Supplement 1A). The autoradiograph of labeled, RNA bound Rpo21 373 
purified by mCRAC (Fig. 5B) shows increased recovery of Rpo21-Ub-RNA complexes in the 374 
bre5∆ strain. However, this was not clearly seen in all replicates. 375 
 376 
The distribution of RNAPII is notably uneven along transcription units (Churchman and 377 
Weissman, 2011; Mayer et al., 2015; Milligan et al., 2016; Nojima et al., 2015). The level of 378 
ubiquitinated Rpo21 recovered via mCRAC was therefore mapped relative to total RNAPII 379 
from the same experiment. Alignment with the transcription start site (TSS) revealed strong 380 
depletion of RNAPII ubiquitination over the promoter proximal region of ~150 nt (Fig. 5D. 381 
Conversely, alignment with the poly(A) site showed that the relative abundance of 382 
ubiquitinated RNAPII peaked ~200 nt upstream of the poly(A) site and then dropped sharply 383 
(Fig. 5E). Alignment of intron containing genes via the 3’ SS showed a peak of ubiquitinated 384 
RNAPII at the 5’ end of the exon 2 region (Fig. 5F). Note that the relatively low number of 385 
intron-containing genes in budding yeast result in a relatively uneven read distribution 386 
profile. In a bre5∆ strain the peaks of ubiquinated RNAPII were elevated immediately 387 
upstream of the poly(A) site (Fig. 5E) and 3’ SS (Fig. 5F), and these differences are 388 
statistically significant (Fig. 5 Supplement 1E-1H). Note, however, that the data are 389 
expressed in reads per million, so increased ubiquitination in the bre5∆ strain is not captured 390 
in the sequence data. Rather Figure 5 and Figure 5 Supplement 1 show alterations in the 391 
relative density of Ub-Rpo21 along the genes. Notably, the distribution of ubiquitinated 392 
RNAPII is in overall agreement with the distribution of Bre5 (Fig. 1) in CRAC analyses. 393 
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 394 
Mutation of the ubiquitination site in Rpo21 decreases cotranscriptional splicing and 395 
alters RNAPII pausing 396 
To test the effects of ubiquitin addition, a K1246R mutant form of Rpo21-HTP was generated 397 
and expressed from the chromosomal RPO21 (RPB1) locus under the control of the 398 
endogenous promoter. Growth of the strain expressing only Rpo21K1246R-HTP was not 399 
clearly different from the wild-type showing the mutant protein to be functional.  400 
 401 
Slowed transcription elongation by RNAPII will be associated with an increased signal in 402 
CRAC analyses, since more time is available for crosslinking to the transcript and the 403 
polymerase density will be higher. If ubiquitination of RNAPII is functionally linked to slowed 404 
elongation, the distribution of the non-ubiquitinated mutant K1246R, which is expected to 405 
reduce pausing, is expected to be anti-correlated with RNAPII-Ub that is associated with 406 
increased pausing. This hypothesis was assessed in CRAC analyses (Fig. 6).  407 
 408 
The distribution Rpo21K1246R was assessed across all protein coding genes and is shown 409 
relative to the wild-type in Figures 6A-6C. Close to the TSS and at the 3’ splice site, the 410 
relative levels of Rpo21K1296R RNAPII were reduced. Note, however, that the data maps the 411 
distribution of RNAPII across genes, so accumulation at any position results in apparent 412 
depletion elsewhere, and vice versa. At the poly(A) site, levels of Rpo21K1296R showed a 413 
minimum ~200 nt upstream of the poly(A) site, but peaked immediately 3’ to the p(A) site. 414 
Around the poly(A) site and at the 3’SS, the distribution of Rpo21K1296R appeared to be 415 
reciprocal to that of Rpo21 ubiquitination, particularly in the bre5∆ background (Fig. 6A-6C). 416 
This supports the model that ubiquitination at K1246 is a physiologically important target of 417 
Bre5-Ubp3. 418 
 419 
If ubiquitin-induced transcription pausing promotes cotranscriptional splicing, this is 420 
predicted to be reduced in strains expressing Rpo21K1246R. Cotranscriptional splicing is 421 
expected to occur prior to 3’ cleavage and polyadenylation, and this was assessed by 422 
determining the levels of unspliced pre-mRNA by qPCR on oligo(dT) primed RT products 423 
(Fig. 6D). For three genes tested, RPL29, RPL25 and ACT1, we saw increased levels of 424 
unspliced, poly(A)+ pre-mRNA in two independent strains expressing Rpo21K1246R.   425 
 426 
Alterations in cotranscriptional splicing were also assessed transcriptome-wide in RNA-seq 427 
experiments performed on total (Ribominus) and poly(A)+ selected RNA. For each individual 428 
intron-containing mRNA, reads mapping to introns and exons were quantified and the ratio 429 
intron/exon (I/E) was calculated and averaged between replicates. To compare transcripts 430 
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from the strains expressing Rpo21-K1246R and the wild-type Rpo21, we then calculated the 431 
log2((I/E)Rpo21-K1246R/(I / E)Rpo21). This value was positive in a metagene analysis of all intron 432 
containing mRNAs (Fig. 6E). Many spliced yeast genes are expressed at low levels during 433 
normal, vegetative growth. Analysis of all individual mRNAs showed increased levels of 434 
unspliced, poly(A)+ RNA for all well-expressed genes (Fig. 6F). This conclusion was further 435 
tested by considering only reads mapping to exon junctions (Fig. 6G). The relative recovery 436 
of spliced mRNA versus unspliced pre-mRNA was expressed as the ratio of reads spanning 437 
exon-intron plus intron-exon to exon-exon junctions ((EI+IE) / 2EE) for each gene (Milligan et 438 
al., 2016; Tuck and Tollervey, 2013). Across all intron-containing genes, the unspliced to 439 
spliced ratio was higher for the Rpo21K1246R mutant compared to the wild-type. 440 
 441 
We also performed the same analyses on total RNA libraries depleted for rRNAs 442 
(Ribominus), which should allow the recovery of nascent transcripts (Figs. 6H-6J). Fewer 443 
reads mapping to mRNAs were recovered with this approach, but an increase in the level of 444 
unspliced pre-mRNA was found for almost all mRNAs with good read density. Figures 6E-6J 445 
show the combined analysis of multiple datasets. Pairwise analyses of individual, replicate 446 
datasets lead to the same conclusions for both poly(A)+ (Fig. 6 Supplement 1A) and 447 
ribominus samples (Fig. 6 Supplement 1B).  448 
 449 
We conclude that single amino acid point mutation at the site of Bre5-Ubp3 sensitive RNAPII 450 
ubiquitination reduces the efficiency of cotranscriptional pre-mRNA splicing, transcriptome-451 
wide.  452 
 453 
 454 
DISCUSSION  455 
The work presented here commenced with the, initially puzzling, identification of Bre5 and 456 
Ubp3 in synthetic-lethal screens with multiple RNA surveillance factors. We speculate that 457 
these negative interactions arise because RNAPII that is paused or stalled in response to 458 
ubiquitination has an increased tendency to release the nascent transcript. Accumulation of 459 
such aberrant RNA fragments in surveillance mutants may result in impaired growth.  460 
 461 
Reproducible sites of ubiquitination were detected at positions K695 and K1246 in Rpo21 462 
(Rpb1), the largest subunit of RNAPII and at K886 in Rpb2, the second largest subunit. 463 
However, only K1246 ubiquitination appeared to be clearly elevated in strains lacking Bre5 464 
or Ubp3, indicating that this is the target of Bre5-Ubp3 activity. The increase in K1246 465 
ubiquitination was more marked in the absence of the deubiquinase Ubp3 than its cofactor 466 
Bre5, perhaps indicating that Ubp3 can also function with other cofactors.  467 
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Sites of Rpo21 ubiquitination were previously identified at K330 and K695, based on the in 468 
vitro activity of the ubiquitin ligase Rsp5 (Somesh et al., 2007). K330 was shown to be 469 
important for the response to UV damage, but this was not the case for K695. However, a 470 
double mutation of Rpo21 K330R plus K695R was lethal, showing that these sites 471 
functionally overlap despite being far apart in the RNAPII structure (Somesh et al., 2007). 472 
Our analysis, in the absence of UV damage, identified ubiquitination at K1246 and K695, but 473 
not K330. This suggests the possibility that in RNAPII stalled by different mechanisms, 474 
splicing versus DNA damage, alternative ubiquitin ligases are recruited that lead to different 475 
primary ubiquitination sites, K1246 versus K330, respectively, with K695 providing an 476 
alternative site in each case. Based on genetic interaction data, we tested Ubr2 as a 477 
candidate E3 ligase, but saw no effects in the splicing reporter construct. A plausible 478 
alternative candidate is the splicing factor Prp19, an E3 ligase that adds K63 ubiquitin chains 479 
to Prp3 during the spicing reaction (Song et al., 2010). However, the ubiquitin ligase activity 480 
of Prp19 is required for splicing to proceed, making it difficult to determine whether it is also 481 
involved in splicing-dependent transcription pausing. Prp3 is deubiquitinated by Usp4 (Song 482 
et al., 2010), and is therefore unlikely to be a target for Bre5-Ubp3.  483 
 484 
The striking similarities between sites of Bre5 binding and elevated Ub-RNAPII, and the anti-485 
correlated pattern in the Rpo21K1246R mutant, strongly support the model that this is the 486 
major, functionally relevant ubiquitination site under normal growth conditions. Bre5 binding 487 
and Ub-RNAPII were both depleted close to the TSS and elevated upstream from the 488 
poly(A) site and in exon 2. The preferential binding of Bre5 and RNAPII ubiquitination in 489 
exon 2 suggested a potential functional relationship to reports of splicing-induced 490 
transcription pausing in this region (Alexander et al., 2010b; Carrillo Oesterreich et al., 491 
2010). Consistent with this, the absence of Bre5 or the loss of its RNA binding activity had 492 
the effect of increasing cotranscriptional splicing efficiency, presumably as a consequence of 493 
increased pausing. Dramatic effects on a splicing reporter construct were seen in the 494 
absence of Bre5 following rapid induction, which were consistent with strongly enhanced 495 
transcription pausing. We postulate that during the initial rounds of cotranscriptional splicing 496 
on a naïve template, the system is more sensitive to perturbation.  497 
 498 
These findings suggest the model that the normal function of splicing-linked RNAPII 499 
ubiquitination is to transiently slow or pause the polymerase in order to promote 500 
cotranscriptional splicing (Fig. 7). To test this hypothesis, we expressed the ubiquitation-501 
resistant Rpo21K1246R mutant, with the expectation that lack of ubiquitation would reduce 502 
transcriptional pausing and, hence, the efficiency of cotranscriptional splicing. This was 503 
shown to be the case for individual genes, which showed increased levels of pre-mRNAs 504 
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that were unspliced but 3’ cleaved and polyadenylated. RNA-seq analyses on total poly(A)+ 505 
selected RNA confirmed this result transcriptome wide, when either all reads mapping to 506 
exons vs intron were compared, or splicing was more specifically assessed by comparing 507 
the ratio of sequence reads spanning exon-exon junction (spliced RNA) to exon-intron plus 508 
intron-exon junctions (unspliced). The finding that splicing was impaired by loss of the 509 
ubiquitination site in RNAPII, supports the model that efficient cotranscriptional splicing 510 
involves a ubiquitination / de-ubiquitination cycle.   511 
 512 
It remains possible that the Rpo21K1246R mutation impairs pre-mRNA splicing independent 513 
of alterations in transcription elongation. Previous analyses have identified important roles 514 
for RNAPII modification in promoting the recruitment of splicing factors. However, this 515 
involved the reversible phosphorylation of residues in the repetitive, regulatory C-terminal 516 
domain (CTD) of the RNAPII large subunit. In contrast, the K1246 ubiquitination site is 517 
distant from both the CTD and the RNA exit channel, making it less likely to directly interact 518 
with either the nascent transcript or the splicing machinery. Alternatively, the K1246R 519 
mutation might be postulated to alter the RNAPII elongation rate independent of RNA 520 
processing events. The sequence data show only relative distribution of RNAPII along 521 
genes, not absolute levels, making changes in global elongation rates hard to assess. 522 
However, previously reported mutations that alter elongation rates all map to the trigger 523 
loop, which is located in the enzymatic center of the polymerase distant from the position of 524 
K1246 (Braberg et al., 2013; Kaplan et al., 2012). 525 
 526 
Given that the large majority of yeast genes lack introns, poly(A) site proximal changes in 527 
RNAPII occupancy and Bre5 binding are presumably generally independent of splicing. 528 
Conversely, elevated Bre5 occupancy at the 5’ end of exon 2 appears to be independent of 529 
cleavage and polyadenylation, since it was observed even on genes with long exon2 regions 530 
(Fig. 1G). Previous reports of slowed RNAPII elongation on exon 2 regions have posited 531 
both splicing-dependent (Alexander et al., 2010b) and splicing-independent (Carrillo 532 
Oesterreich et al., 2010) mechanisms. It may be that both conclusions are correct, with 533 
different mechanisms operating at different locations. The mechanism by which 534 
ubiquitination might slow elongation has not been determined but, as indicated in Fig. 4F, 535 
the position of the ubiquitin moiety on the catalytic component of RNAPII might be expected 536 
to interfere with entry of the DNA duplex into the active site. An alternative, non-exclusive, 537 
possibility might that ubiquitin addition interferes with back-tracking of stalled RNAPII 538 
complexes.  539 
 540 
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Major changes in RNAPII phosphorylation and apparent processivity take place close to the 541 
site of pre-mRNA 3’ cleavage and polyadenylation (reviewed in (Conaway and Conaway, 542 
2015; Hsin and Manley, 2012; Porrua and Libri, 2015)). We speculate that a surveillance or 543 
RNAPII remodeling step may occur upstream of the poly(A) site, as recently proposed for 544 
human cells (Laitem et al., 2015). This location is apparently associated with RNAPII 545 
ubiquitination as shown by the peaks of Ub-RNAPII and Bre5 binding at this position. 546 
RNAPII that is ubiquitination-resistant due to the Rpo21K1296R mutation showed a notably 547 
reduced density upstream of the poly(A) site relative to total RNAPII. This indicates that it 548 
may be less prone to pausing in this region and potentially avoids this surveillance activity. 549 
However, the Rpo21K1296R RNAPII shows increased occupancy downstream of the poly(A) 550 
site. We speculate that changes to RNAPII that would normally accompany the pause 551 
upstream of the poly(A) site are absent or reduced in the Rpo21K1296R mutant, leading to 552 
subsequent impairment of transcript release.  553 
 554 
Finally, we note that Ubp3 was previously reported to interact with the chromatin-silencing 555 
factor Sir4, along with Sir2 and Sir3, while loss of Ubp3 was reported to increase the 556 
efficiency of gene silencing near telomeres and the inactive HML mating type locus (Moazed 557 
and Johnson, 1996). Based on our data, we hypothesize that this reflects increased RNAPII 558 
pausing or stalling in silenced genomic regions in the absence of Bre5-Ubp3 mediated 559 
deubiquitination. We also note that several recent reports link changes in alternative pre-560 
mRNA splicing in human cells to RNAPII elongation rates (reviewed in (Naftelberg et al., 561 
2015; Saldi et al., 2016)) and speculate that reversible ubiquitination of the transcribing 562 
polymerase may participate in regulating this activity.   563 
 564 
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MATERIALS AND METHODS 575 
Strains and yeast culture 576 
Standard procedures were used for the propagation and maintenance of yeast. All strains 577 
were constructed using a one-step PCR strategy. A full list of Saccharomyces cerevisiae 578 
strains used in this study can be found in Supplementary File 1, Table S3.  579 
 580 
RNA binding assays using in-vitro transcribed and translated proteins 581 
Binding of [35S]-labeled Bre5 and Ubp3 to homopolymeric nucleotides and biotinylated, in 582 
vitro-transcribed RNA was performed as previously described (Milligan et al., 2008; 583 
Oeffinger et al., 2004). Equivalent amounts of protein recovered from bound, unbound, and 584 
total fractions were separated by SDS-PAGE on a 4 to 12% Bis-Tris gel. Following 585 
migration, the gel was dried and protein was visualized by autoradiography. 586 
 587 
RNA binding assays using HTP-tagged proteins purified from yeast 588 
Cells lysis was performed essentially as described (Granneman et al., 2011). Bre5-HTP and 589 
Nab3-HTP were recovered from the lysate by binding to Dynabeads M-270 Epoxy 590 
(Invitrogen) coupled to rabbit IgG (Sigma) as described (Fridy et al., 2014). The bound 591 
protein was then resuspended in RNA binding buffer (100 mM NaCl, 20 mM Tris (pH 7.4), 592 
10% glycerol, 0.1 mM EDTA, 4 mM MgCl2, 1 mM DTT, 40 μg of bovine serum albumin/ml, 593 
200 μg of tRNA ml-1). RNA binding was initiated by adding 2 pmol of radio-labeled RNA 594 
oligonucleotide to 3 pmol of bound protein and incubated at room temperature for 30 min. 595 
The unbound fraction was removed, the beads were washed and resuspended in RNA 596 
loading buffer. The unbound and bound fractions were analyzed on a 12% acrylamide, 8.3M 597 
Urea gel. 598 
 599 
CRAC 600 
In vivo UV crosslinking at 254 nm in actively growing cells, RNA purification and cDNA 601 
generation were performed essentially as described (Granneman et al., 2011; Schneider et 602 
al., 2012). Following UV crosslinking, Bre5-HTP was recovered from the lysate by binding of 603 
the 2 copies of the Protein A tag to an IgG column and elution by TEV cleavage, essentially 604 
as described (Granneman et al., 2011; Schneider et al., 2012).  RNA-protein complexes 605 
were subjected to partial RNase degradation, denatured by addition of Guanidinium HCl to 606 
4M final concentration and bound to a nickel column via the His6 tag on Bre5. Linkers were 607 
added to the Bre5-associated RNAs on the nickel column and the bound protein-RNA 608 
complexes were eluted with imidazole and gel purified by SDS-PAGE (Figure 1 Supplement 609 
1). Following proteinase K digestion, RNAs were identified by reverse transcription and PCR 610 
amplification, followed by Illumina HiSeq sequencing (performed by Edinburgh Genomics, 611 
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Source Biosystems) or Illumina miniSeq sequencing (performed in house). 612 
 613 
mCRAC analysis of ubiquitinated RNA PolII 614 
In vivo UV crosslinking in actively growing cells, RNA purification and cDNA generation and 615 
were performed essentially as described (Granneman et al., 2009; Schneider et al., 2012). 616 
UV crosslinking at 254 nm was performed on actively growing cells, and Rpo21-HTP was 617 
recovered from the lysate by binding of the Protein A tag to an IgG column and elution by 618 
TEV cleavage, essentially as described (Granneman et al., 2009; Schneider et al., 2012). 619 
Ubiquitinated Rpo21-HTP was separated using MultiDsk protein (Wilson et al., 2012). RNA-620 
protein complexes were subjected to partial RNase degradation, denatured by addition of 621 
Guanidinium HCl to 4M to denature and remove them from the MultiDsk column and bound 622 
to a nickel column via the His6 tag on Rpo21. Linkers were added to the Rpo21-associated 623 
RNAs on the nickel column and the bound protein-RNA complexes were eluted with 624 
imidazole and gel purified by SDS-PAGE. Following proteinase K digestion, RNAs were 625 
identified by reverse transcription and PCR amplification, followed by Illumina sequencing. 626 
Illumina sequencing was performed by Edinburgh Genomics and Source Biosystems. 627 
 628 
Sequence data analysis for CRAC and mCRAC  629 
Reads were pre-processed, aligned and analyzed as described (Milligan et al., 2016). The 630 
distribution of reads across transcript classes was determined using pyReadCounters from 631 
pyCRAC (Webb et al., 2014) and using genome annotation from Ensembl (EF4.74), 632 
supplemented with non-coding sequences as previously described (Tuck and Tollervey, 633 
2013). For the metagene analysis, protein coding genes and exon 2 contain 5171 and 288 634 
features, respectively (Xu et al., 2009). 635 
 636 
For Bre5 motif analysis, Bre5 reads were preprocessed using FLEXBAR (Dodt et al., 2012) 637 
with the parameters –at 1 –ao 4 and were filtered to retain only reads containing the 3′ 638 
adaptor. PCR duplicates were removed using pyFastqDuplicateRemover from pyCRAC 639 
(Webb et al. 2014). Reads were filtered to exclude low-complexity sequences (with more 640 
than 80% of one nucleotide) (Tuck and Tollervey, 2013). Reads were mapped to the yeast 641 
genome by using novoalign from Novocraft. PCR duplicates that were not collapsed during 642 
preprocessing due to sequencing errors or differential trimming at the 3’ end were collapsed 643 
(Tuck and Tollervey, 2013). After the exclusion of reads mapping to RNAPI and RNAPIII 644 
transcripts or originating from the mitochondrial genome (Sayou et al., 2017), reads mapping 645 
to protein coding genes and containing single nucleotide deletions (indicating the precise 646 
nucleotide crosslinked to the bait protein) were selected using pyReadCounters from 647 
pyCRAC (Webb et al., 2014). To remove biases in sequence representation caused by 648 
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abundantly expressed genes, overlapping reads were assembled into a single sequence 649 
using pyClusterReads from pyCRAC (Webb et al. 2014). A motif search was carried out 650 
using MEME (Bailey et al., 2015) on 2 different sets of 500 sequences for each dataset. A 651 
motif search was also done using the complete datasets using pyMotif from pyCRAC (Webb 652 
et al., 2014) and gave similar results. The 2 Bre5-HTP replicates were analyzed and gave a 653 
similar motif. Nab3 CRAC sequences were analyzed using the same pipeline and recovered 654 
the Nab3 motif (Bresson et al., 2017). CRAC sequences from Rpo21 (this study), the 655 
untagged BY4741 strain (this study), Set1 and Set2 (Sayou et al., 2017) were also analyzed 656 
as negative control and no motifs were found. CRAC sequences generated during this work 657 
have been deposited with GEO; accession number GSE94944, subseries GSE94941.  658 
 659 
Immunoprecipitation and Western blotting 660 
For analysis of the ubiquitination levels of Rpo21, cells were grown in YPD at 30°C to 661 
OD=0.5 Whole cell lysates of cells were then prepared and immunoprecipitation was carried 662 
out with both an antibody against Rpb3 (1Y26, Neoclone, RRID:AB_1129174) and an anti-663 
ubiquitin antibody (ab19247, Abcam, RRID:AB_444805). The immunoprecipitates were then 664 
separated by SDS-PAGE on a 4 to 12% Bis-Tris gel and transferred to nitrocellulose 665 
membrane (Hybond C, GE Lifesciences).  666 
 667 
RiboSys analysis 668 
The RiboSys reporter used in this study was previously described (Alexander et al 2010). 669 
The RIBO1 reporter (Fig. 2A) contains part of the PGK1 open reading frame with the 670 
insertion of the ACT1 pre-mRNA intron, integrated into the chromosomal HIS3 locus under 671 
the control of an inducible tetO7 promoter. Cultures were pre-grown in synthetic dropout 672 
(SD) medium (Formedium) to OD600nm 0.5, transcription was repressed or induced by the 673 
addition of doxycycline to 4 μg/mL and aliquots were snap-frozen by pipetting into an equal 674 
volume of methanol sitting on dry ice. The frozen cells in the methanol slurry were pelleted 675 
by centrifugation and stored at −80°C. 676 
 677 
RNA extraction and RT-qPCR. 678 
RNA was extracted as previously described (Tollervey 1987).  Prior to the conversion to 679 
cDNA, 10 ug of total RNA was treated with Turbo-DNA free (Ambion) according to the 680 
681 
DNase treated RNA using Retroscript (Ambion) with random decamers. cDNA was then 682 
diluted 1 / 20. qPCRs were performed in triplicate with Sensimix SYBR low-rox kit (Bioline) in 683 
a Stratagene MX3005P real-time PCR machine. Cycling parameters were 2min at 94°C, 684 
then 50 cycles of 10s at 94oC, 10s at 63oC and 20s at 72oC. For the endogenous 685 
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transcripts, cDNA was prepared from 5ug of the DNase treated RNA using Retroscript 686 
(Ambion) with oligodT. cDNA was then diluted 1 / 20. qPCRs were performed in triplicate 687 
with Sensimix SYBR low-rox kit (Bioline) in a Stratagene MX3005P real-time PCR machine. 688 
Cycling parameters were 10 min at 95˚C, then 40 cycles of 15s at 95˚C, 15s at 55˚C and 15s 689 
at 72˚C. 690 
 691 
ChIP analysis 692 
For ChIP analysis, 40 ml aliquots of culture were crosslinked for 10 min with 1% (v/v) 693 
formaldehyde and treated as described at http://www.ribosys.org/, using antibodies against 694 
Rpb3p (1Y26, Neoclone, RRID:AB_1129174). The DNA fragments (average size 350 bp) 695 
were amplified by qPCR using primers listed in Supplementary File 1, Table S4. ChIP data 696 
for the kinetic experiments are presented as percentage of input relative to uninduced level 697 
at T0. Experiments presented were performed at least in triplicate, with all qPCR assays 698 
also performed in triplicate. In each case, a representative experiment is shown. 699 
 700 
Protein Expression and Purification 701 
MultiDsk was expressed and purified as previously described (Wilson et al, 2003). MultiDsk 702 
expression plasmid pGST-MD was propagated in BL-21 (DE3) cells. Transformed cells were 703 
grown overnight in starter culture in LB with 100 µg/ml ampicillin at 37°C. 600 ml of LB-Amp 704 
was inoculated with overnight starter culture and allowed to reach an optical density (OD600) 705 
of 0.6. IPTG was added to a final concentration of 1 mM, and the culture was shifted to 30°C 706 
for 4 hours. Cells were harvested by centrifugation at 6000 g for 15 min, washed once in 707 
PBS, and frozen in liquid nitrogen. Cells were lysed and protein solubilized essentially as 708 
described (Frangioni and Neel, 1993). Briefly, thawed pellets were resuspended in STE 709 
buffer (10 mM Tris pH 8, 1 mM EDTA, 100 mM NaCl, 1× Protease Inhibitor mix [284 ng/ml 710 
leupeptin, 1.37 µg/ml pepstatin A, 170 µg/ml phenylmethylsulfonyl fluoride and 330 µg/ml 711 
benzamindine]) with N-lauryl sarcosine added to a final concentration of 1.5%. After brief 712 
sonication and centrifugation, Triton X-100 was added to the supernatant to a final 713 
concentration of 3%, to mask the sarcosine. 0.8 ml of pre-equilibrated glutathione agarose 714 
beads (GE healthcare) were added to this solution, and the slurry incubated for 2–4 hours at 715 
4°C. The beads were washed thoroughly in STE buffer containing 500 mM NaCl and 0.1% 716 
Triton X-100, followed by a 50 mM NaCl wash in the same buffer. The beads were then 717 
used directly for the mCRAC. 718 
 719 
RNA-seq 720 
RNA was extracted as previously described (Tollervey, 1987). The RNA samples were either 721 
enriched for mRNA using NEBNext Oligo d(T)25 (New England Biolabs) or depleted of rRNA 722 
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using RiboMinus (Life Technologies) according to the manufacturer’s instructions, producing 723 
poly(A)+ or total RNA libraries, respectively. High throughput sequencing libraries were 724 
prepared using NEBNext Ultra Directional RNA Library Prep Kit for Illumina according to the 725 
manufacturer’s instructions. Illumina sequencing was carried out by Edinburgh Genomics. 726 
For each total RNA or polyA+ RNA libraries, 2 and 4 biological replicates were obtained for 727 
the strains expressing Rpo21-HTP (Rpo21) and Rpo21-K1246R-HTP (Rpo21-K1246R), 728 
respectively. Sequenced reads were reverse complement using FASTX Toolkit, adaptors 729 
were trimmed and reads were quality filtered using Trimmomatic (Bolger et al., 2014). Reads 730 
were mapped to the yeast genome (S. cerevisiae genome version EF4.74, from Ensembl) 731 
using STAR (Dobin et al., 2013). To evaluate the splicing efficiency in the Rpo21-K1246R 732 
strain relative to the Rpo21 strain, reads mapping to introns (I) and exons (E) were counted 733 
in each dataset and for each intron-containing mRNA, using the Bedtools suite (Quinlan and 734 
Hall 2010) and based on genome annotations from Ensembl (EF4.74). The ratio (I+1) / 735 
(E+1) (the pseudo-count of 1 avoids numerical instabilities) and the total count I+E were 736 
calculated for each transcript and averaged between replicates. The log2((I+1 / E+1)Rpo21-737 
K1246R/(I+1 / E+1)Rpo21) indicated whether a transcript was relatively more recovered as 738 
unspliced (positive value) or spliced (negative value) in the mutant compared to the wild-739 
type. To select for transcripts with enough coverage, we used those with I+E above the 740 
mean (I+E) in both wild-type and mutant datasets in the polyA+ RNA libraries, resulting in a 741 
subset of 101 transcripts. We obtained a similar size subset for the total RNA libraries by 742 
selecting the 100 top transcripts based on I+E ranking. In a complementary approach, the 743 
relative abundance of unspliced and spliced reads was calculated as described (Milligan et 744 
al., 2016; Tuck and Tollervey, 2013). Briefly, reads were aligned to a database containing 745 
pre-mRNAs and mature mRNAs using Novoalign (Novocraft). The relative number of reads 746 
spanning the unspliced junctions (exon-intron, EI and intron-exon, IE) to spliced (exon-exon, 747 
EE) was calculated as (EI+IE) / 2EE for each transcript and averaged between replicates. 748 
The log2([(EI+IE) / 2EE Rpo21-K1246R] / [(EI+IE) / 2EE Rpo21]) value was calculated for each 749 
transcript and indicated whether a transcript was relatively more recovered as unspliced 750 
(positive value) or spliced (negative value) in the mutant compared to the wild-type. RNA-751 
seq sequences generated during this work have been deposited with GEO; accession 752 
number GSE94944, subseries GSE94942.  753 
https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?token=gdufwymgpnmlxmh&acc=GSE94944 754 
 755 
Affinity purification of Rpb3-TAP for analytical mass spectrometry 756 
Affinity purification of Rpb3-TAP was performed as previously (Rigaut et al., 1999) with the 757 
following modifications. Frozen yeast pellets, obtained from exponentially growing cells in 758 
synthetic medium minus tryptophan (optical density of 0.6 at 600nm), after induction of His6-759 
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Ubiquitin with 0.1mM CuSO4, were resuspended in TMN150 buffer (50 mM Tris-HCl pH 7.8, 760 
150 mM NaCl, 1.5 mM MgCl2, 0.1% NP-40, 5 mM beta-mercaptoethanol, 20 M Lactacystin, 761 
2mM N-ethylmalemide). Clarified extract was incubated with IgG-Sepharose for 2 h at 4°C. 762 
Washes and TEV cleavage were performed in TMN150 buffer. The ubiquitylated sub-units 763 
were purified via the His6-tagged ubiquitin on a Ni-NTA sepharose column, eluted and 764 
separated by SDS-PAGE and silver stained. 765 
 766 
SDS-PAGE analysis and in-gel digestion  767 
The entire lane of the coomassie-stained gel was chopped into small pieces, destained and 768 
digested as described (Shevchenko et al., 1996). In brief, proteins were reduced in 10 mM 769 
dithiothreitol for 30 min at 37°C, alkylated in 55 mM iodoacetamide for 20 min at room 770 
temperature in the dark, and digested at 37°C overnight with 12.5 ng/μl trypsin (Proteomics; 771 
Grade; Sigma). Following digestion samples were then acidified with equal volume of 0.1% 772 
of trifluoroacetic acid and spun onto StageTips (Rappsilber et al., 2003). Peptides were 773 
eluted in 20 μl 80% acetonitrile, 0.1% trifluoroacetic acid and were concentrated to 2 μl 774 
(concentrator 5301; Eppendorf AG, Hamburg, Germany). They were then diluted to 5 μl with 775 
0.1% trifluoroacetic acid for liquid chromatography-tandem mass spectroscopy (LC-MS-MS) 776 
analysis.  777 
 778 
Affinity purification of Rpb3-TAP for quantitative mass spectrometry  779 
Affinity purification of Rpb3-TAP was performed as previously (Rigaut et al., 1999) with the 780 
following modifications. Frozen yeast pellets from untagged and Rpb3-TAP, Rpb3TAP/ 781 
∆bre5 and Rpb3-TAP/∆ubp3 cells, obtained from exponentially growing cells in YPDA 782 
(optical density of 0.6 at 600nm), were resuspended in TMN150 buffer (50 mM Tris-HCl pH 783 
7.8, 150 mM NaCl, 1.5 mM MgCl2, 0.1% NP-40, 5 mM beta-mercaptoethanol, 20 M 784 
Lactacystin, 2mM N-ethylmalemide). Clarified extract was incubated with Dynabeads M-270 785 
Epoxy (Invitrogen) coupled to rabbit IgG (Sigma) as described (ref Fridy et al. Nature 786 
Protocols 2014) for 1 h at 4°C. Bound protein was denatured off the column in 0.1% 787 
Rapigest (Waters) for 30 minutes at 60˚C. The samples were then prepared for Mass 788 
spectrometry by Filter-aided sample preparation (FASP) (Wisniewski et al., 2009). In brief, 789 
proteins were reduced in 10 mM dithiothreitol for 30 min at 37°C, alkylated in 55 mM 790 
iodoacetamide for 20 min at room temperature in the dark, and digested at 37°C overnight 791 
with 12.5 ng/μl trypsin (Proteomics; Grade; Sigma). Following digestion samples were then 792 
acidified with equal volume of 0.1% of trifluoroacetic acid and spun onto StageTips 793 
(Rappsilber et al., 2003). Peptides were eluted in 20 μl 80% acetonitrile, 0.1% trifluoroacetic 794 
acid and were concentrated to 2 μl (concentrator 5301; Eppendorf AG, Hamburg, Germany). 795 
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They were then diluted to 5 μl with 0.1% trifluoroacetic acid for liquid chromatography-796 
tandem mass spectroscopy (LC-MS-MS) analysis. tandem mass spectroscopy (LC-MS-MS) 797 
analysis.  798 
 799 
MS analysis 800 
Analytic MS analyses were performed on an LTQ-Orbitrap Velos mass spectrometer 801 
(Thermo Fisher Scientific, Bremen, Germany), coupled online to an Ultimate 3000 802 
RSLCnano Systems (Dionex, Thermo Fisher Scientific, UK). To prepare an analytical 803 
column with a self-assembled particle frit (Ishihama et al., 2002), C18 material (3-μm 804 
ReproSil-Pur C18-AQ; Maisch GmbH, Ammerbuch-Entringen, Germany) was packed into a 805 
spray emitter (75-μm inner diameter, 8-μm opening, 70-mm length; New Objectives, United 806 
States) by using an air pressure pump (Proxeon Biosystems, Odense, Denmark). Mobile 807 
phase A consisted of 0.1% formic acid in water and mobile phase B of 80% acetonitrile 808 
in0.1% formic acid. Peptides were loaded onto the column at a flow rate of 0.5 μL min-1 and 809 
eluted at a flow rate of 0.2 μL min-1 according to the following gradient: 2 to 40% mobile 810 
phase B in 150 min and then to 95% in 11 min. Mobile phase B was then reduced to 2% 811 
until 180 min. FTMS spectra were recorded at 60,000 resolution (scan range 300-1700 m/z) 812 
and the twenty most intense peaks with charge ≥ 2 of the MS scan were selected with an 813 
isolation window of 2.0 Thomson in the ion trap for MS2 (normal scan, wideband activation, 814 
filling 5.0E5 ions for MS scan, 1.0E4 ions for MS2, maximum fill time 100 ms, dynamic 815 
exclusion for 60 s). Searches were conducted using the MASCOT search engine (Matrix 816 
Science) against the complete Saccharomyces cerevisiae protein database 817 
(Saccharomyces Genome Database, November 2009). MS accuracy was set to 6 ppm and 818 
MS/MS tolerance to ±0.6 Da. Trypsin was used as enzyme allowing two missed cleavages. 819 
Carbamidomethylation of cysteine was chosen as fixed modification, while oxidation of 820 
methionine and di-glycine of lysine were chosen as variable modifications.   821 
 822 
For quantitative MS, all targeted analyses were performed on high resolution/accurate mass 823 
Orbitrap Fusion Lumos instrument (Thermo) coupled to Ultimate3000 RSLC system fitted 824 
with EasySpray column (50cm 2μm particles). Targeted analyses were performed in 825 
scheduled tSIMtMS2 mode with a following parameters – 1.6m/z isolation window, AGC 826 
target was set to 5e4 for both MS1 and MS2 and injection time was set to 70ms. Retention 827 
time and m/z of targeted peptides were selected on the base of the prior experiments. Data 828 
analyses was performed in Skyline 3.7 (MacLean et al., 2010), using the following filtering 829 
settings: retention time was considered within 4min of MS/MS ID, and mass tolerance at 830 
fragment ion level – 4ppm. The four most intense fragment ions were used for quantitation. 831 
832 
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 1022 
FIGURE LEGENDS 1023 
Figure 1. Bre5 binds RNA in vitro and in vivo  1024 
A: Bre5 and Ubp3 plus Bre5 bind RNA in vitro. Recombinant Bre5 and Ubp3 were 1025 
expressed in E.coli individually and in combination, and bound to the biotinylated 1026 
oligonucleotides indicated, which were immobilized on streptavidin agarose columns.  1027 
B: Tagged Bre5 and Nab3 were purified from yeast, along with a mock-purified, untagged 1028 
control, and assayed for binding to labeled RNA oligonucleotides.  1029 
1: polyA (AAAAAAAAAAAAAAAAAAAAAAAAA ),  1030 
2: polyG (GGGGGGGGGGAGGGGGGGGGGAGGGGG)  1031 
3: polyU (UUUUUUUUUUUUUUUUUUUUUUUUU ),  1032 
4: polyC (CCCCCCCCCCACCCCCCCCCCACCCCC ),  1033 
5: polyA/U (AUAUAUAUAUAUAUAUAUAUAUAU ),  1034 
6: Nab3-A (AAAAAUCUUAAAUCUUAAAUCUUAAAAA ),  1035 
7 Nab3-U (UUUUUUCUUUUUUCUUUUUUCUUUUUUU),  1036 
8: Bre5-A (AAAAAUUUGAAAUUUGAAAUUUGAAAAA ),  1037 
9: Bre5-U (UUUUUUUUGUUUUUUGUUUUUUGUUUUU). The y axis represents the signal 1038 
quantified from the bound oligos (arbitrary units), the errors bars are the standard deviation 1039 
from 3 biological replicates. See also Fig. 1 Supplement 1A-1C. 1040 
C: Distribution of RNA sequences recovered with Bre5-HTP and the untagged control 1041 
across different RNA classes. 15-fold fewer reads were recovered with the control 1042 
(Supplementary File 1, Table S2) and numbers of mapped reads are indicated below the bar 1043 
graphs.  1044 
D: Metagene analysis of the distribution of RNA sequences recovered with Bre5 across 1045 
protein coding transcripts (5171 features) (Xu et al., 2009), in reads per million (RPM). 1046 
Sequences were aligned relative to the transcription start site (TSS). The average of 2 Bre5 1047 
CRAC replicates is shown. The standard deviation appears as a grey shadow. 1048 
E: As D, but sequences were aligned relative to the poly(A) site (pA).  1049 
F: Metagene analysis of the distribution of RNA sequences recovered with Bre5 across 1050 
intron containing, protein coding transcripts (288 features), in RPM. Sequences were aligned 1051 
relative to the 3’ splice site (3’SS). The average of 2 Bre5 CRAC replicates is shown. The 1052 
standard deviation appears as a grey shadow. 1053 
G: As F, but data were filtered to show only genes with long exon2 regions (above 600 nt, 1054 
145 features). 1055 
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H: As F, but data were filtered to show only genes with short exon2 regions (below 600 nt, 1056 
143 features). 1057 
 1058 
Figure 2. Analysis of ribosys reporter induction  1059 
A: Diagram of theRibo1 gene. Exons are represented by rectangles, and the intron by a line 1060 
with sequences at the ends. The reporter genes are based on previously described ACT1-1061 
PGK1 constructs (Alexander et al., 2010b; Hilleren and Parker, 2003) expressed under 1062 
control of a tetO7-CYC1-UAS promoter (BellÌ et al., 1998). The lines above indicate 1063 
amplicons analyzed in ChIP analyses: 1, 2, 3, 4, and 5 correspond to the promoter, the 5′SS, 1064 
the 3′SS, the 5′ end of exon 2 and the 3′ end of exon 2, respectively. The lines below 1065 
indicate the primers used in RT-qPCR to amplify the spliced RNA products. Unspliced pre-1066 
rRNA was detected using primer pair 3 over the 3’ SS.  1067 
B: RT-qPCR analysis of the accumulation of pre-mRNA and mRNA species during a time 1068 
course (min) following doxycyclin addition (T0). Analyses were performed on the wild-type, 1069 
bre5∆ and ubr2∆ strains as indicated.  1070 
C, D, E, F, G: ChIP analyses to detect RNAPII at the promoter (probe 1), the 5′SS (probe 2), 1071 
the 3′SS (probe 3), the 5′ end of exon 2 (probe 4) and the 3′ end of exon 2 (probe 5). Data 1072 
are presented as percentage of input relative to the uninduced level at T0. Cultures were as 1073 
for B. All analyses were performed in biological triplicates. The qualitative results were 1074 
consistent between replicates, however, slight differences in induction kinetics makes it 1075 
difficult to combine these for statistical analyses. The graphs therefore show single 1076 
experiments with technical replicates. 1077 
 1078 
Figure 3. Strains lacking functional Bre5 show decreased co-transcriptional splicing  1079 
A: RT-qPCR analysis of endogenous, polyadenylated and intron containing transcripts using 1080 
primer pairs over the 3’ splice site expressed relative to non-intron-containing PGI1 mRNA, 1081 
in a wild type strain and in a strain lacking Bre5. The histogram shows the mean of three 1082 
replicates with standard error, with the value in the BRE5 strain set to 1. The reduced level 1083 
of unspliced poly(A)+ shows increased efficiency of cotranscriptional splicing associated with 1084 
RNAPII that has has reached the 3’ end of the transcription unit. 1085 
B: Analysis of in-vivo RNA binding activity of Bre5 with point mutants in the RRM. The top 1086 
panel shows the recovery of radio-labelled RNA that was bound to Bre5 following in vivo 1087 
crosslinking and multi-step, denaturing purification and separation by SDS-PAGE as 1088 
described for CRAC analyses. The lower panel shows a Western blot using an anti-TAP 1089 
antibody against the tagged Bre5.  1090 
C: RT-qPCR analysis of endogenous unspliced, polyadenylated transcripts using primer 1091 
pairs over the 3’ splice site expressed relative to non-intron-containing PGI1 mRNA. The 1092 
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histogram in a wild type HTP-tagged Bre5 strain and in strains carrying the point mutations 1093 
in the RRM. The histogram shows the mean of three experiments with standard error, with 1094 
the value in the strain expressing wild type Bre5 set to 1. The reduced level of unspliced, 1095 
poly(A)+ RNA in the mutant strains is interpreted as showing a requirement for a functional 1096 
RRM in Bre5.  1097 
 1098 
Figure 4. Identification of ubiquitination sites in RNAPII  1099 
A: Analysis of Rpo21immunoprecipitated from wild type cells, cells lacking Bre5 and cells 1100 
lacking Ubp3 using an anti-ubiquitin antibody followed by Western blotting using an antibody 1101 
against Rpo21. 1102 
B: Analysis of Rpo21immunoprecipitated from wild type cells, cells lacking Bre5 and cells 1103 
lacking Ubp3 using an anti-Rpb3 antibody followed by Western blotting using an anti-1104 
ubiquitin antibody. 1105 
C: Table showing the ubiquitinated Rpo21 peptides from wild type cells, cells lacking Bre5 1106 
and cells lacking Ubp3, identified by mass spectrometry.  1107 
D: Quantitation of modified and unmodified peptides derived from the region surrounding 1108 
Rpo21 K1246. 1109 
D: PRM-based quantitation of peptide harboring Rpo21 K1246-Ub.  The sum of XICs 1110 
(Extracted Ion Chromatogram) corresponding to the four most intense ions was used to 1111 
calculate the total area under curve and taken as a value representing recovery of Rpo21 1112 
K1246-Ub. The abundance of Rpo21 K1246-Ub in the wild type sample was used for 1113 
normalization. Ratios of Rpo21 K1246-Ub identified in untagged, bre5Δ and ubp3Δ strains 1114 
are shown relative to the wild type.   1115 
E: The structure of RNAPII was taken from PDB: 4bbs (Sainsbury et al., 2013) and kindly 1116 
prepared by Altanta Cook (Edinburgh University). Protein residues are shown in gray, with 1117 
the single stranded DNA template in red and the RNA transcript in blue. The ubiquitation site 1118 
in Rpo21 at K1246 is not visible in the crystal structure, but the neighboring sites at P1245 and 1119 
E1253 are shown in magenta.   1120 
F: As panel D but with ubiquitin drawn in the approximate position of the crosslink and at a 1121 
similar scale. 1122 
 1123 
Figure 5. Transcriptome wide distribution of ubiquitinated Rpo21 by m-CRAC 1124 
A: Outline of the m-CRAC procedure. Actively growing cells expressing Rpo21-HTP (His6 -1125 
TEV cleavage site – 2 copies of the Z domain of protein A) were UV-crosslinked at 254nm 1126 
for 1 min. Following lysis, Rpo21-HTP was affinity purified on an IgG column and released 1127 
by TEV cleavage.  Ubiquinated proteins were enriched on a GST-MultiDsk column (GST-1128 
MD) or mock enriched over GST alone. Associated RNA was partially denatured by RNase 1129 
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treatment, followed by protein denaturation by addition of guanidinium HCl to 4M. Denatured 1130 
Rpo-21-His was bound to a Nickel column in the same buffer. Following washing, bound 1131 
RNAs were 5’ labeled with [32P], and linkers were added to both ends. Proteins were eluted 1132 
with imidazole and separated by SDS-PAGE. Rpo21-RNA complexes were localized by 1133 
autoradiography, excised from the gel and digested with proteinase K. RNAs released by 1134 
this treatment were amplified by RT-PCR and identified by Illumina sequencing. 1135 
B: Autoradiograph of labeled RNA bound to Rpo21 and purified by mCRAC. The top panel 1136 
shows Rpo21 from wild type cells and the bottom panel from cells lacking Bre5.  1137 
C: Bar chart showing ubiquitinated Rpo21 binding to different RNA classes. 1138 
D: Metagene analysis of the distribution of ubiquitinated Rpo21 enrichment relative to total 1139 
Rpo21, across protein coding transcripts (5171 features) (Xu et al., 2009) aligned to the TSS 1140 
in wild type cells (blue line) and cells lacking Bre5 (green line). The x axis shows the relative 1141 
position in nt. The average of 2 m-CRAC replicates is shown, the standard deviation is 1142 
shown in Fig. 5 Supplement 1. 1143 
E: As D, but transcripts were aligned to the pA sites. 1144 
F: Metagene analysis of the distribution of ubiquitinated Rpo21 enrichment relative to total 1145 
Rpo21, across intron containing transcripts (288 features) relative to the 3’SS in wild type 1146 
cells (blue line) and cells lacking Bre5 (green line). The x axis shows the relative position in 1147 
nt. The average of 2 m-CRAC replicates is shown. The standard deviation is shown in Fig. 4, 1148 
supplement 1. 1149 
 1150 
Figure 6. Loss of RNAPII ubiquitation is associated with reduced pausing and co-1151 
transcriptional splicing 1152 
A: Metagene analysis of the distribution of Rpo21K1246R relative to wild-type Rpo21 (purple 1153 
line) and ubiquitinated Rpo21 relative to total Rpo21 in strains lacking Bre5 (green line) 1154 
across protein coding transcripts relative to the TSS. The x axis shows the relative position 1155 
in nt. The average of 2 replicates is shown. 1156 
B: As A, but transcripts were aligned to the pA sites. 1157 
C: Metagene analysis of the distribution of Rpo21K1246R relative to wild-type Rpo21 (purple 1158 
line) and ubiquitinated Rpo21 relative to total Rpo21 in strains lacking Bre5 (green line) 1159 
across intron containing transcripts relative to the 3’ SS. The x axis shows the relative 1160 
position in nt. The average of 2 replicates is shown. 1161 
D: Quantitation of selected intron-containing transcripts by qPCR on oligo(dT) primed 1162 
cDNAs, in a strain expressing Rpo21-HTP (blue bars) or Rpo21K1246R-HTP (green bars). 1163 
The histogram shows the mean of three replicates with standard error. 1164 
E: Reads mapping to introns and exons were quantified in RNA-seq libraries prepared from 1165 
poly(A)+ RNA and the average intron/exon ratio (I/E) was calculated. The boxplot shows the 1166 
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distribution of log2((I/E)Rpo21-K1246R/(I/E)Rpo21) values for the top represented, intron-1167 
containing mRNAs (n=101). The data indicate higher intron recovery in poly(A)+ RNAs in the 1168 
Rpo21-K1246R mutant. 1169 
F: For each intron-containing gene (n=296), the log2((I/E)Rpo21-K1246R/(I/E)Rpo21) from 1170 
poly(A)+ reads is plotted against the number of reads mapped to this gene. Almost all genes 1171 
with enough coverage to be confidently analyzed (well-detected genes)  1172 
(have a positive ratio, showing that cotranscriptional splicing efficiency was reduced in the 1173 
Rpo21-K1246R strain compared to wild-type. Confidently detected genes (n=101) used for 1174 
Fig. 6E and Fig. 6 Supplement 1A are highlighted. 1175 
G: The relative recovery of unspliced pre-mRNA versus spliced mRNA (Unspl/Spl) was 1176 
expressed as the ratio of reads spanning (exon-intron plus intron-exon) to exon-exon 1177 
junctions in the poly(A)+ RNA-seq libraries. For most mRNAs with sufficient coverage at the 1178 
splice junctions (n=85), the log2 ratio of (Unsp/Spl) of Rpo21-K1246R to Rpo21 was 1179 
positive, indicating increased recovery of unspliced, polyadenylated pre-mRNAs 1180 
H: As panel E, but using RNA depleted for rRNA (Ribominus) with confidently detected 1181 
genes (n=100). 1182 
I: As panel F, but using RNA depleted for rRNA (Ribominus). Confidently detected genes 1183 
(n=100) used for Fig. 6G and Fig. 6 Supplement 1B are highlighted 1184 
J: As panel G. Relative recovery of unspliced versus spliced RNA (Unspl/Spl) was 1185 
expressed as the ratio of reads spanning (exon-intron plus intron-exon) to exon-exon 1186 
junctions recovered in total RNA depleted for rRNAs (n=49). 1187 
 1188 
Figure 7. Model for splicing-linked RNAPII ubiquitination and de-ubiquitination  1189 
A: Transcription on intron-containing gene. Exon 1 (E1), intron (I), exon2 (E2) and the C-1190 
terminal domain (CTD) of RNA polymerase II (RNAPII) are indicated. 1191 
B: Assembly of the spliceosome provokes RNAPII ubiquinitation and slowed elongation. 1192 
C: Bre5-Ubp3 is recruited to the nascent transcripts following splicing. 1193 
D: De-ubiquinitation by Ubp3 allows elongation to resume.  1194 
 1195 
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SUPPLEMENTARY FILE 1 1196 
The file contains supplementary Tables S1-S4. 1197 
 1198 
SOURCE DATA 1199 
The Source Data file contains 12 Excel spreadsheets:  1200 
Figure 1B_source data 1201 
Figure2_source data 1202 
Figure2 replicates_source data 1203 
Figure2 supplement1 ChIP1_source data 1204 
Figure2 supplement1 ChIP2_source data 1205 
Figure2 supplement1 ChIP3_source data 1206 
Figure2 supplement1 RT1_source data 1207 
Figure2 supplement1 RTs2&3_source data 1208 
Figure3A_source data 1209 
Figure3C_source data 1210 
Figure 4D_source data 1211 
Figure 6D_source data 1212 
 1213 
SUPPLEMENTARY FIGURE LEGENDS 1214 
Figure 1 Supplement 1 Bre5 binding to RNA is independent of Ubp3 or the ubiquitin 1215 
ligase Rsp5 1216 
A: Related to Fig. 1A. Labeled oligonucleotides were incubated with purified Bre5-HTP, 1217 
Nab3-HTP or a mock-purified untagged control. Following washing, oligos were eluted and 1218 
recovery was analyzed by polyacrylamide gel separation and autoradiography. 1219 
Oligonucleotides used were:  1220 
1: polyA (AAAAAAAAAAAAAAAAAAAAAAAAA ),  1221 
2: polyG (GGGGGGGGGGAGGGGGGGGGGAGGGGG)  1222 
3: polyU (UUUUUUUUUUUUUUUUUUUUUUUUU ),  1223 
4: polyC (CCCCCCCCCCACCCCCCCCCCACCCCC ),  1224 
5: polyA/U (AUAUAUAUAUAUAUAUAUAUAUAU ),  1225 
6: Nab3-A (AAAAAUCUUAAAUCUUAAAUCUUAAAAA ),  1226 
7 Nab3-U (UUUUUUCUUUUUUCUUUUUUCUUUUUUU),  1227 
8: Bre5-A (AAAAAUUUGAAAUUUGAAAUUUGAAAAA ),  1228 
9: Bre5-U (UUUUUUUUGUUUUUUGUUUUUUGUUUUU).  1229 
B: Preferred Bre5 binding motif derived from Bre5-HTP bound sequences in CRAC, 1230 
generated using the MEME suite. 1231 
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C: SDS=PAGE analysis showing purification of Bre5-HTP (lanes 2, 5 and 7) or Nab3 (lane 1232 
3) used for the RNA binding assay shown in panel A.  1233 
D: Bre5 binding across protein coding transcripts relative to the TSS in wild type cells (grey 1234 
line) and cells lacking Ubp3 (green lines).  1235 
E: Bre5 binding across protein coding transcripts relative to the pAS in wild type cells (grey 1236 
line) and cells lacking Ubp3 (green lines). 1237 
F: Bre5 binding across protein coding transcripts relative to the 3’SS in wild type cells (grey 1238 
line) and cells lacking Ubp3 (green lines). 1239 
G: Bre5 binding across protein coding transcripts relative to the TSS in wild type cells (blue 1240 
line) and cells carrying a temperature sensitive allele of Rsp5 (green line) at non-permissive 1241 
temperature. 1242 
H: Bre5 binding across protein coding transcripts relative to the pAS in wild type cells (blue 1243 
line) and cells carrying a temperature sensitive allele of Rsp5 (green line) at non-permissive 1244 
temperature. 1245 
I: Bre5 binding across protein coding transcripts relative to the TSS in wild type cells (blue 1246 
line) and cells carrying a temperature sensitive allele of Rsp5 (green line) at non-permissive 1247 
temperature. 1248 
 1249 
Supp. Figure 1 Supplement 2. Distribution of Bre5 across individual genes 1250 
A: Distribution of Bre5 across individual mRNAs in reads per million. Transcripts are aligned 1251 
to the TSS (left) and to the pA site (middle). Intron containing mRNAs are aligned to the 1252 
3’SS (right). Distances are indicated in nucleotides.  The corresponding total coverages are 1253 
shown in Fig. 1D-F. The average of 2 Bre5 CRAC replicates is shown.  1254 
B: Bre5 coverage, in reads per million, for selected individual protein coding genes. 1255 
Transcription units are represented above the plots with thicker boxes correspond to coding 1256 
sequences. The average of 2 Bre5 CRAC replicates is shown. 1257 
 1258 
Figure 2 Supplement 1. Effects of Bre5 loss on the Ribosys reporter is splicing 1259 
dependent  1260 
A: Diagram of the Ribo1 5’SS gene. Exons are represented by rectangles, and the intron by 1261 
a line with sequences at the ends. The red cross indicates a mutation at the 5’SS which 1262 
abolishes splicing. The lines above indicate amplicons analyzed in RT-qPCR or ChIP 1263 
analyses: 1, 2, 3, 4, and 5 correspond to the promoter, the 5′SS, the 3′SS, the 5′ end of exon 1264 
2 and the 3′ end of exon 2, respectively.  1265 
B: RT-qPCR analysis of accumulation of pre-mRNA and mRNA species showing the 1266 
increase compared to time of doxycyclin addition (T0) in the wild-type strain (panel on the 1267 
left) and in a strain lacking Bre5 (right panel). 1268 
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C, D, E, F, G: ChIP analysis (presented as percentage of input relative to uninduced level at 1269 
T0) to detect RNAPII at the promoter, the 5′SS, the 3′SS, the 5′ end of exon 2 and the 3′ end 1270 
of exon 2, respectively with the same cultures as above. 1271 
 1272 
Figure 4 Supplement 1. Quantitative MS analyses  1273 
A: Fragmentation and spectral library match of peptide harboring Rpo21 K1246 modification.  1274 
B: Example of extracted ion chromatograms (XIC) of y18-y10 ions used for quantification of 1275 
the modified peptide. Area under curve of all co-eluting transitions within mass error of 4ppm 1276 
was considered.  1277 
 1278 
Figure 5 Supplement 1. Analysis of transcriptome wide distribution of ubiquitinated 1279 
Rpo21 by mCRAC 1280 
A: Western blot analysis of protein purified from Rpo21-HTP cell extracts using the MultiDsk 1281 
column (lane 4) or GST alone (lane 3). 6% of the flow through from these columns was 1282 
loaded in lanes 1 and 2. The top panel shows a Western with an anti-ubiquitin antibody, the 1283 
bottom one with an anti-TAP antibody. 1284 
B: Histogram showing the number of unique reads recovered by Illumina Sequencing. 1285 
C: As Figure 5D showing the standard error from the triplicate experiments for the wild type 1286 
strain. 1287 
D: As Figure 5D showing the standard error from the triplicate experiments for the strain 1288 
deleted for Bre5. 1289 
E: As Figure 5E but showing the standard error from the triplicate experiments for the wild 1290 
type strain. 1291 
F: As Figure 5E but showing the standard error from the triplicate experiments for the strain 1292 
deleted for Bre5. 1293 
G: As Figure 5F but showing the standard error from the triplicate experiments for the wild 1294 
type strain. 1295 
H: As Figure 5F but showing the standard error from the triplicate experiments for the strain 1296 
deleted for Bre5. 1297 
 1298 
Figure 6 Supplement 1. Strains carrying a point mutation in the ubiquitinated LK1246 1299 
residue show loss of pausing at the 3’ splice site and a reduction in co-transcriptional 1300 
splicing. 1301 
A: As Fig. 6F but showing comparisons of individual replicates instead of using the average 1302 
I/E. In all cases, the log2((I/E)Rpo21-K1246R/(I/E)Rpo21) values for the top represented 1303 
intron-containing mRNAs (n=101) is positive, indicating a relative higher recovery of 1304 
unspliced mRNAs in the Rpo21K1246R mutant compared to the wild type. 1305 
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B: As Fig, 6I but showing comparisons of individual replicates instead of using the average 1306 
(n=100).  1307 
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